Overview of EID2B: A Promising Drug Target for Cancer (G126272)

Target Name: EID2B

NCBI ID: G126272

EID2B

Overview of EID2B: A Promising Drug Target for Cancer

The identification of potential drug targets is a critical step in the development of new treatments for various diseases. One of the promising targets in the field of cancer research is the EID-2-like inhibitor of differentiation 3 (EID2B), which has been shown to have potential in the treatment of various types of cancer. In this article, we will provide an overview of EID2B, including its structure, function, and potential as a drug target.

Structure and Function

EID2B is a protein that belongs to the EID2 family of proteins. This family is known for its role in cell signaling and division, with EID2B being a key member of this family. EID2B is expressed in various tissues and cells of the body, including cancer cells, and has been shown to play a role in the development and progression of various types of cancer.

One of the key functions of EID2B is its ability to inhibit the process of differentiation, which is the process by which stem cells develop into different cell types. This is important because cancer cells are able to maintain their undifferentiated state, which allows them to continue to grow and multiply without being controlled by the cell cycle. By inhibiting the process of differentiation, EID2B has been shown to have potential as a drug target for cancer.

EID2B has been shown to work by binding to a specific protein called nuclear factor of activated T cells (NFAT), which is a transcription factor that plays a role in the regulation of cellular processes such as cell growth, differentiation, and inflammation. By binding to NFAT, EID2B has been shown to prevent NFAT from activating and leading to the transcription of genes that are involved in the process of differentiation.

EID2B has also been shown to work by inhibiting the activity of a protein called p53, which is a well-known tumor suppressor protein. p53 is involved in the regulation of various cellular processes, including DNA repair and cell apoptosis (programmed cell death). By inhibiting the activity of p53, EID2B has been shown to prevent its ability to prevent the formation of DNA repair repair, which can lead to the survival of cancer cells.

Potential as a Drug Target

The potential of EID2B as a drug target is currently being investigated for various types of cancer. Studies have shown that EID2B has the potential to be a useful drug target for several types of cancer, including breast, ovarian, and colorectal cancers.

In breast cancer, EID2B has been shown to have the potential to slow down or even stop the growth of cancer cells. This is achieved by inhibiting the activity of NFAT and p53, which are involved in the regulation of cell growth and differentiation. This has led to the potential of EID2B as a treatment for breast cancer.

In ovarian cancer, EID2B has been shown to have the potential to slow down the growth of cancer cells by inhibiting the activity of NFAT and p53. This has led to the potential of EID2B as a treatment for ovarian cancer.

In colorectal cancer, EID2B has been shown to have the potential to slow down the growth of cancer cells by inhibiting the activity of NFAT and p53. This has led to the potential of EID2B as a treatment for colorectal cancer.

Conclusion

In conclusion, EID2B is a protein that has been shown to have potential as a drug target for cancer. Its structure and function, as well as its ability to inhibit the process of differentiation and its interaction with important proteins like NFAT and

Protein Name: EP300 Interacting Inhibitor Of Differentiation 2B

Functions: Acts as a repressor of MYOD-dependent transcription, glucocorticoid receptor-dependent transcription, and muscle differentiation

The "EID2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EID2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets